HHS Secretary Robert F. Kennedy Jr. (center), CMS Administrator Mehmet Oz (right) and FDA Commissioner Marty Makary (left) announced biosimilar reform plans at a Wednesday HHS news conference.
Federal health officials on Wednesday announced new biosimilar reform efforts, which aim to more quickly and cheaply develop the lower [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
